• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    LifeMD Appoints William J. Febbo to its Board of Directors

    6/20/23 8:00:00 AM ET
    $LFMD
    $OPRX
    Medical/Nursing Services
    Health Care
    Business Services
    Consumer Discretionary
    Get the next $LFMD alert in real time by email

    NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the appointment of William (Will) J. Febbo, Chief Executive Officer and Director of OptimizeRx Corporation (NASDAQ:OPRX) to its Board of Directors. OptimizeRx is a leading provider of digital point-of-care technology solutions that help patients start and stay on therapy.

    "We are extremely pleased to welcome Will to our Board. He brings to LifeMD a depth of experience in building and managing healthcare companies, and pioneering technology to improve the experience for healthcare providers and patients," said Justin Schreiber, Chairman and Chief Executive Officer of LifeMD. "Will's success in leading OptimizeRx's growth with investment in AI-driven optimization, real-time marketing, and personalized patient engagement offers a particularly valuable perspective as we continue to scale our primary-care business and pursue our mission to increase access to high-quality and affordable virtual care."

    "I know firsthand that providing patients with access to exceptional healthcare when and where they need it requires best-in-class technology, clinical resources, and patient engagement," said Mr. Febbo. "I am impressed by LifeMD's continued success with launching new product offerings, building a B2B pipeline, and strengthening the balance sheet – each of which is necessary to help remove the complex barriers that stand between a patient and appropriate healthcare provider. I look forward to collaborating with LifeMD's Board and leadership to help make the delivery of healthcare services more accessible, affordable, and patient-centric."

    For more than 25 years Mr. Febbo has built and managed health services and financial businesses, starting in M&A and international business development at multinational companies. In 1999 he co-founded and subsequently served as Chief Executive Officer of MedPanel, a market intelligence and communication provider to the life sciences and financial industries. In 2007 MedPanel was acquired by Merriman Capital, where he served as Chief Operating Officer of investment banking and as Chief Executive Officer of the firm's Digital Capital Network. In 2016 Mr. Febbo joined OptimizeRx, where he helped transform the firm into a leading digital health company enabling care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey.

    Mr. Febbo serves as a faculty member for the Massachusetts Institute of Technology linQ program, a collaborative initiative increasing the potential of innovative biomedical research to benefit society and the economy. He also serves on the board of the United Nations of Greater Boston, a non-profit organization focused on building a stronger network of global citizens in the Boston area.

    About LifeMD

    LifeMD is a leading provider of virtual primary care. The Company offers telemedicine, laboratory and pharmacy services, and specialized treatment across more than 200 conditions including primary care, men's health, women's health, allergy & asthma, and dermatology. Leveraging a vertically-integrated, proprietary digital care platform, a 50-state affiliated medical group, and a US-based patient care center, LifeMD is simplifying healthcare by increasing access to top-notch and affordable care. For more information, please visit LifeMD.com.

    Media Contact

    [email protected]

    Investor Contact

    Marc Benathen, CFO

    [email protected]



    Primary Logo

    Get the next $LFMD alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $LFMD
    $OPRX

    CompanyDatePrice TargetRatingAnalyst
    LifeMD Inc.
    $LFMD
    6/18/2025$15.00 → $18.00Buy
    BTIG Research
    OptimizeRx Corporation
    $OPRX
    1/8/2025$7.00 → $6.00Outperform → Sector Perform
    RBC Capital Mkts
    OptimizeRx Corporation
    $OPRX
    12/20/2024$5.50Equal-Weight
    Stephens
    LifeMD Inc.
    $LFMD
    12/10/2024$12.00Buy
    Lake Street
    LifeMD Inc.
    $LFMD
    12/4/2024$7.00Neutral
    Mizuho
    LifeMD Inc.
    $LFMD
    8/23/2024$11.00Buy
    B. Riley Securities
    OptimizeRx Corporation
    $OPRX
    7/25/2024$18.50Buy
    B. Riley Securities
    LifeMD Inc.
    $LFMD
    6/5/2024$12.00Overweight
    KeyBanc Capital Markets
    More analyst ratings

    $LFMD
    $OPRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • OptimizeRx Corporation Appoints CEO Steve Silvestro to Board of Directors

      WALTHAM, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced the appointment of Steve Silvestro, currently serving as the Company's Chief Executive Officer, to its Board of Directors, effective as of June 20, 2025. Mr. Silvestro joined the Company in 2019 and has been the Company's CEO since March 2025, after serving as the interim CEO from January 2025. The appointment of Mr. Silvestro, with his knowledge of the Company and expertise in the industry, will enhance overall leadership and gre

      6/24/25 7:30:00 AM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

      NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (NASDAQ:LFMDP) equal to $0.5546875 per share. The preferred dividend will be paid on July 15, 2025, to holders of record at the close of business on July 3, 2025. About LifeMD, Inc. LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men's and women's heal

      6/23/25 4:05:00 PM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • Simulmedia and OptimizeRx Announce Partnership from the Cannes Lions

      Strategic Collaboration Brings Precision Micro-Neighborhood® Targeting Healthcare Consumer Audiences to Linear and Connected TV Simulmedia, a national leader in data-driven TV and streaming advertising, today announced a strategic partnership with OptimizeRx Corp. (NASDAQ:OPRX), a leading provider of healthcare technology solutions, to enable the self-serve availability of Micro-Neighborhood® Targeting (MNT) audiences across linear, digital, and connected TV (CTV) channels. This collaboration allows healthcare brands—especially small and mid-size pharmaceutical companies and in-house planning teams—to activate clinically precise audiences across guaranteed premium TV and streaming inven

      6/18/25 3:00:00 AM ET
      $OPRX
      Business Services
      Consumer Discretionary

    $LFMD
    $OPRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research reiterated coverage on LifeMD with a new price target

      BTIG Research reiterated coverage of LifeMD with a rating of Buy and set a new price target of $18.00 from $15.00 previously

      6/18/25 10:55:14 AM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • OptimizeRx downgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts downgraded OptimizeRx from Outperform to Sector Perform and set a new price target of $6.00 from $7.00 previously

      1/8/25 8:17:01 AM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • Stephens initiated coverage on OptimizeRx with a new price target

      Stephens initiated coverage of OptimizeRx with a rating of Equal-Weight and set a new price target of $5.50

      12/20/24 7:46:38 AM ET
      $OPRX
      Business Services
      Consumer Discretionary

    $LFMD
    $OPRX
    Financials

    Live finance-specific insights

    See more
    • LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

      NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (NASDAQ:LFMDP) equal to $0.5546875 per share. The preferred dividend will be paid on July 15, 2025, to holders of record at the close of business on July 3, 2025. About LifeMD, Inc. LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men's and women's heal

      6/23/25 4:05:00 PM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • OptimizeRx Reports First Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance

      Q1 revenue of $21.9 million, increasing 11% year-over-yearQ1 gross profit increased 9% year-over-year to $13.3 millionIncreases full year 2025 guidance to a revenue range between $101 million and $106 million and adjusted EBITDA range between $13 million and $15 million WALTHAM, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today reported results for the three months ended March 31, 2025. Quarterly comparisons are to the same year-ago period. Financial Highlights Revenue in the first quarter of 2025

      5/12/25 4:05:00 PM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • Medifast Announces First Quarter 2025 Financial Results

      Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the first quarter ended March 31, 2025. First Quarter 2025 Revenue of $115.7 million, with revenue per active earning coach of $4,556 Independent active earning OPTAVIA coaches of 25,400 Net loss of $0.8 million, which includes an unrealized gain on investment in LifeMD (NASDAQ:LFMD) common stock of $0.4 million (net of tax) Loss per share of $0.07 Cash, Cash Equivalents, and Investment Securities of $164.6 million with no debt "In today's health and wellness landscape, more people than ever are seeking guidance not just for we

      4/28/25 4:05:00 PM ET
      $LFMD
      $MED
      Medical/Nursing Services
      Health Care
      Packaged Foods
      Consumer Staples

    $LFMD
    $OPRX
    SEC Filings

    See more
    • OptimizeRx Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - OptimizeRx Corp (0001448431) (Filer)

      6/24/25 7:45:08 AM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • LifeMD Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - LifeMD, Inc. (0000948320) (Filer)

      6/16/25 4:43:54 PM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • OptimizeRx Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - OptimizeRx Corp (0001448431) (Filer)

      6/16/25 4:29:49 PM ET
      $OPRX
      Business Services
      Consumer Discretionary

    $LFMD
    $OPRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Lang James Paul bought $2,443,761 worth of shares (321,408 units at $7.60), increasing direct ownership by 472% to 389,452 units (SEC Form 4)

      4 - OptimizeRx Corp (0001448431) (Issuer)

      3/19/25 7:40:24 PM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • CEO Febbo William J bought $100,220 worth of shares (20,000 units at $5.01), increasing direct ownership by 3% to 601,253 units (SEC Form 4)

      4 - OptimizeRx Corp (0001448431) (Issuer)

      12/16/24 2:28:39 PM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • Chief Innovation Officer Galluppi Stefan bought $14,790 worth of shares (3,000 units at $4.93), increasing direct ownership by 7% to 45,449 units (SEC Form 4)

      4 - LifeMD, Inc. (0000948320) (Issuer)

      9/12/24 2:10:03 PM ET
      $LFMD
      Medical/Nursing Services
      Health Care

    $LFMD
    $OPRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chairman and CEO Schreiber Justin sold $334,458 worth of shares (25,000 units at $13.38) (SEC Form 4)

      4 - LifeMD, Inc. (0000948320) (Issuer)

      7/3/25 3:53:16 PM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • Chief Financial Officer Benathen Marc David sold $1,682,440 worth of shares (125,000 units at $13.46), decreasing direct ownership by 27% to 339,554 units (SEC Form 4)

      4 - LifeMD, Inc. (0000948320) (Issuer)

      6/18/25 6:18:00 PM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • Chief Legal Officer & GC Yecies Eric Harold sold $183,750 worth of shares (15,000 units at $12.25) (SEC Form 4)

      4 - LifeMD, Inc. (0000948320) (Issuer)

      6/17/25 6:12:19 PM ET
      $LFMD
      Medical/Nursing Services
      Health Care

    $LFMD
    $OPRX
    Leadership Updates

    Live Leadership Updates

    See more
    • OptimizeRx Corporation Appoints CEO Steve Silvestro to Board of Directors

      WALTHAM, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced the appointment of Steve Silvestro, currently serving as the Company's Chief Executive Officer, to its Board of Directors, effective as of June 20, 2025. Mr. Silvestro joined the Company in 2019 and has been the Company's CEO since March 2025, after serving as the interim CEO from January 2025. The appointment of Mr. Silvestro, with his knowledge of the Company and expertise in the industry, will enhance overall leadership and gre

      6/24/25 7:30:00 AM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • OptimizeRx Corporation Announces Plan for Additional Board of Directors Refreshment

      WALTHAM, Mass., April 18, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that, as part of OptimizeRx's ongoing process to refresh and expand its board of directors (the "Board"), it intends to appoint a new independent director to its Board of Directors during the second half of this year.  With the appointment of a new independent director in 2025, OptimizeRx will have refreshed its Board, which is currently comprised of five directors, with three new directors since 2020, including Catherine Klema w

      4/18/25 4:15:53 PM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • OptimizeRx Corporation Appoints Stephen Silvestro as Chief Executive Officer

      WALTHAM, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced it has appointed Steve Silvestro as the Company's new Chief Executive Officer, effective March 10, 2025. Mr. Silvestro brings to OptimizeRx more than 20 years of experience in building and managing health technology and services companies, and has served as an executive at OptimizeRx since joining the Company in 2019. His career includes strategic development, sales leadership, technology and product innovation, and M&A within a

      3/10/25 7:30:00 AM ET
      $OPRX
      Business Services
      Consumer Discretionary

    $LFMD
    $OPRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by OptimizeRx Corporation

      SC 13G/A - OptimizeRx Corp (0001448431) (Subject)

      12/6/24 4:26:03 PM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • SEC Form SC 13G filed by OptimizeRx Corporation

      SC 13G - OptimizeRx Corp (0001448431) (Subject)

      11/14/24 3:18:35 PM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by OptimizeRx Corporation

      SC 13G/A - OptimizeRx Corp (0001448431) (Subject)

      11/14/24 11:25:34 AM ET
      $OPRX
      Business Services
      Consumer Discretionary